Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

MACROGENICS INC Director's Dealing 2020

Aug 21, 2020

34129_dirs_2020-08-21_c0ba81db-881e-4c10-a07c-4188c6531ebf.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: MACROGENICS INC (MGNX)
CIK: 0001125345
Period of Report: 2020-08-20

Reporting Person: Spitznagel Thomas (Sr VP, BPD & Manufacturing)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2020-08-20 Common Stock M 7500 $7.51 Acquired 7500 Direct
2020-08-20 Common Stock S 7500 $26.87 Disposed 0 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2020-08-20 Employee stock option (right to buy) $7.51 M 7500 Disposed 2023-09-17 Common Stock (7500.0) Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2020.

F2: This transaction was executed in multiple trades at prices ranging from $26.54 to $27.27. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staffof the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3: 12.5% of the shares underlying the grant become (or became) exercisable on the date reflected and an additional 6.25% of the shares underlying the grant become (or became) exercisable on the first day of each three-month period thereafter.